\nMaterialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing and medical software and of sophisticated 3D printing services, today announced its financial results for the first quarter ended March 31, 2023.<\/p>\n
Highlights \u2013 First Quarter 2023<\/b><\/p>\n \nExecutive Chairman Peter Leys commented, \u201cMaterialise performed extremely well in the year\u2019s opening quarter. Our consolidated revenues increased more than 24%, boosted by the very strong growth of Materialise Medical and Materialise Manufacturing revenues, by 33% and 25% respectively, and further supported by a solid revenue uptake at Materialise Software of more than 8%. During the quarter, our Adjusted EBITDA increased 89% to 10,310 kEUR, mainly because of scaling effects.\u201d<\/p>\n First Quarter 2023 Results<\/b><\/p>\n \nTotal revenue for the first quarter of 2023 increased 24.4% to 65,886 kEUR from 52,961 kEUR for the first quarter of 2022. Adjusted EBITDA increased to 10,310 kEUR for the first quarter of 2023 from 5,443 kEUR for the 2022 period. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the first quarter of 2023 was 15.6%, compared to 10.3% for the first quarter of 2022.<\/p>\n \nRevenue from Materialise Software increased 8.3% to 11,350 kEUR for the first quarter of 2023 from 10,483 kEUR for the same quarter last year. Segment Adjusted EBITDA increased to 2,427 kEUR from 1,932 kEUR while the segment Adjusted EBITDA margin was 21.4% compared to 18.4% for the prior-year period.<\/p>\n \nRevenue from our Materialise Medical segment increased 32.5% to 24,317 kEUR for the first quarter of 2023 compared to 18,347 kEUR for the same period in 2022. Segment Adjusted EBITDA increased to 7,348 kEUR for the first quarter of 2023 compared to 3,227 kEUR while the segment Adjusted EBITDA margin grew to 30.2% compared to 17.6% for the first quarter of 2022.<\/p>\n \nRevenue from our Materialise Manufacturing segment increased 25.2% to 30,219 kEUR for the first quarter of 2023 from 24,131 kEUR for the first quarter of 2022. Segment Adjusted EBITDA increased to 3,189 kEUR from 2,613 kEUR while the segment Adjusted EBITDA margin was 10.6% compared to 10.8% for the first quarter of 2022.<\/p>\n \nGross profit grew to 36,837 kEUR compared to 28,884 kEUR for the same period last year, while gross profit as a percentage of revenue increased to 55.9% compared to 54.5% for the first quarter of 2022.<\/p>\n \nResearch and development (\u201cR&D\u201d), sales and marketing (\u201cS&M\u201d) and general and administrative (\u201cG&A\u201d) expenses increased, in the aggregate, 8.7% to 32,358 kEUR for the first quarter of 2023 from 29,774 kEUR for the first quarter of 2022.<\/p>\n \nNet other operating income was 519 kEUR compared to 938 kEUR for the first quarter of 2022.<\/p>\n \nOperating result amounted to 4,998 kEUR compared to 49 kEUR for the first quarter of 2022.<\/p>\n \nNet financial result was (566) kEUR compared to 376 kEUR for the first quarter of 2022.<\/p>\n \nThe first quarter of 2023 contained income tax expenses of (718) kEUR, compared to (298) kEUR in the first quarter of 2022.<\/p>\n \nAs a result of the above, net profit for the first quarter of 2023 was 3,715 kEUR, compared to 127 kEUR for the same period in 2022. Total comprehensive income for the first quarter of 2023, which includes exchange differences on translation of foreign operations, was 4,490 kEUR compared to 1,543 kEUR for the 2022 period.<\/p>\n \nAt March 31, 2023, we had cash and cash equivalents of 141,720 kEUR compared to 140,867 kEUR at December 31, 2022. Gross debt amounted to 75,251 kEUR, compared to 80,980 kEUR at December 31, 2022. As a result, our net cash position (gross debt less cash and cash equivalents) increased 6,582 kEUR to 66,469 kEUR.<\/p>\n \nCash flow from operating activities for the first quarter of 2023 decreased to 11,044 kEUR from 11,111 kEUR for the same period in 2022. Total capital expenditures for the first quarter of 2023 amounted to 3,271 kEUR.<\/p>\n \nNet shareholders\u2019 equity at March 31, 2023 was 233,251 kEUR compared to 228,928 kEUR at December 31, 2022.<\/p>\n 2023 Guidance<\/b><\/p>\n \nExecutive Chairman Peter Leys concluded, \u201cIn the beginning of 2023, we expected Materialise to report consolidated revenue between 255,000 kEUR and 260,000 kEUR and Adjusted EBITDA between 25,000 kEUR and 30,000 kEUR. Based on the company\u2019s strong Q1 performance, but also bearing in mind the uncertain global macro-economic environment, we now believe that our 2023 revenue will come closer to the high end of the initially guided range, and expect that our 2023 Adjusted EBITDA could be up to 10% higher than the top of the range communicated earlier.\u201d<\/p>\n Non-IFRS Measures<\/b><\/p>\n \nMaterialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding share-based compensation expenses, acquisition-related expenses of business combinations, impairments and revaluation of fair value due to business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company\u2019s day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company\u2019s business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company\u2019s ability to grow or as a valuation measurement. The company\u2019s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company\u2019s presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.<\/p>\n Exchange Rate<\/b><\/p>\n \nThis document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.0875, the reference rate of the European Central Bank on March 31, 2023.<\/p>\n Conference Call and Webcast<\/b><\/p>\n \nMaterialise will hold a conference call and simultaneous webcast to discuss its financial results for the first quarter of 2023 on Thursday, April 27, 2023, at 8:30 a.m. ET\/2:30 p.m. CET. Company participants on the call will include Wilfried Vancraen, Founder and Chief Executive Officer; Peter Leys, Executive Chairman; and Johan Albrecht, Chief Financial Officer. A question-and-answer session will follow management\u2019s remarks.<\/p>\n \nTo access the call by phone, please click the link below at least 15 minutes prior to the scheduled start time and you will be provided with dial-in details. Participants can choose to dial in or receive a call to connect to Materialise\u2019s conference call.<\/p>\n \nThe conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company\u2019s website at http:\/\/investors.materialise.com<\/a>. A webcast of the conference call will be archived on the company’s website.<\/p>\n About Materialise<\/b><\/p>\n \nMaterialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise\u2019s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com<\/a>.<\/p>\n Cautionary Statement on Forward-Looking Statements<\/b><\/p>\n \nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our current estimates for fiscal 2023 revenue and Adjusted EBITDA, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the ongoing military conflict between Ukraine and Russia and economic sanctions related thereto as well as by inflation and increased labor, energy and materials costs), and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words \u201cestimate,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cproject,\u201d \u201cplan,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201caim,\u201d \u201cshould,\u201d and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company’s actual results to differ materially from our expectations, including risk factors described in the company’s most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained in this press release.<\/p>\n \nThe company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.<\/p>\n Consolidated income statements (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n 2023<\/b><\/p>\n<\/td>\n 2023<\/b><\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n<\/tr>\n \n71,651<\/p>\n<\/td>\n \n65,886<\/p>\n<\/td>\n \n52,961<\/p>\n<\/td>\n<\/tr>\n \n(31,591)<\/p>\n<\/td>\n \n(29,049)<\/p>\n<\/td>\n \n(24,078)<\/p>\n<\/td>\n<\/tr>\n 40,060<\/b><\/p>\n<\/td>\n 36,837<\/b><\/p>\n<\/td>\n 28,884<\/b><\/p>\n<\/td>\n<\/tr>\n \n55.9%<\/p>\n<\/td>\n \n55.9%<\/p>\n<\/td>\n \n54.5%<\/p>\n<\/td>\n<\/tr>\n \n(9,802)<\/p>\n<\/td>\n \n(9,014)<\/p>\n<\/td>\n \n(7,814)<\/p>\n<\/td>\n<\/tr>\n \n(15,539)<\/p>\n<\/td>\n \n(14,288)<\/p>\n<\/td>\n \n(13,515)<\/p>\n<\/td>\n<\/tr>\n \n(9,848)<\/p>\n<\/td>\n \n(9,056)<\/p>\n<\/td>\n \n(8,444)<\/p>\n<\/td>\n<\/tr>\n \n565<\/p>\n<\/td>\n \n519<\/p>\n<\/td>\n \n938<\/p>\n<\/td>\n<\/tr>\n 5,436<\/b><\/p>\n<\/td>\n 4,998<\/b><\/p>\n<\/td>\n 49<\/b><\/p>\n<\/td>\n<\/tr>\n \n(1,495)<\/p>\n<\/td>\n \n(1,375)<\/p>\n<\/td>\n \n(1,289)<\/p>\n<\/td>\n<\/tr>\n \n880<\/p>\n<\/td>\n \n809<\/p>\n<\/td>\n \n1,665<\/p>\n<\/td>\n<\/tr>\n \n–<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n<\/tr>\n 4,821<\/b><\/p>\n<\/td>\n 4,432<\/b><\/p>\n<\/td>\n 425<\/b><\/p>\n<\/td>\n<\/tr>\n \n(780)<\/p>\n<\/td>\n \n(718)<\/p>\n<\/td>\n \n(298)<\/p>\n<\/td>\n<\/tr>\n 4,041<\/b><\/p>\n<\/td>\n 3,715<\/b><\/p>\n<\/td>\n 127<\/b><\/p>\n<\/td>\n<\/tr>\n \n–<\/p>\n<\/td>\n \n4,047<\/p>\n<\/td>\n \n3,721<\/p>\n<\/td>\n \n134<\/p>\n<\/td>\n<\/tr>\n \n(7)<\/p>\n<\/td>\n \n(7)<\/p>\n<\/td>\n \n(7)<\/p>\n<\/td>\n<\/tr>\n \n0.07<\/p>\n<\/td>\n \n0.06<\/p>\n<\/td>\n \n0.00<\/p>\n<\/td>\n<\/tr>\n \n0.07<\/p>\n<\/td>\n \n0.06<\/p>\n<\/td>\n \n0.00<\/p>\n<\/td>\n<\/tr>\n \n59,067<\/p>\n<\/td>\n \n59,067<\/p>\n<\/td>\n \n59,064<\/p>\n<\/td>\n<\/tr>\n \n59,070<\/p>\n<\/td>\n \n59,070<\/p>\n<\/td>\n \n59,102<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Consolidated statements of comprehensive income (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n 2023<\/b><\/p>\n<\/td>\n 2023<\/b><\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n 4,041<\/b><\/p>\n<\/td>\n 3,715<\/b><\/p>\n<\/td>\n 127<\/b><\/p>\n<\/td>\n \n843<\/p>\n<\/td>\n \n776<\/p>\n<\/td>\n \n1,416<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n 843<\/b><\/p>\n<\/td>\n 776<\/b><\/p>\n<\/td>\n 1,416<\/b><\/p>\n<\/td>\n 4,883<\/b><\/p>\n<\/td>\n 4,490<\/b><\/p>\n<\/td>\n 1,543<\/b><\/p>\n<\/td>\n 4,890<\/b><\/p>\n<\/td>\n 4,496<\/b><\/p>\n<\/td>\n 1,549<\/b><\/p>\n<\/td>\n \n(6)<\/p>\n<\/td>\n \n(6)<\/p>\n<\/td>\n \n(7)<\/p>\n<\/td>\n Consolidated statement of financial position (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n 2023<\/b><\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n<\/tr>\n \n44,196<\/p>\n<\/td>\n \n44,155<\/p>\n<\/td>\n<\/tr>\n \n36,944<\/p>\n<\/td>\n \n37,875<\/p>\n<\/td>\n<\/tr>\n \n94,462<\/p>\n<\/td>\n \n94,276<\/p>\n<\/td>\n<\/tr>\n \n8,323<\/p>\n<\/td>\n \n8,420<\/p>\n<\/td>\n<\/tr>\n \n–<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n<\/tr>\n \n1,208<\/p>\n<\/td>\n \n1,186<\/p>\n<\/td>\n<\/tr>\n \n3,555<\/p>\n<\/td>\n \n3,494<\/p>\n<\/td>\n<\/tr>\n \n307<\/p>\n<\/td>\n \n307<\/p>\n<\/td>\n<\/tr>\n \n5,414<\/p>\n<\/td>\n \n5,136<\/p>\n<\/td>\n<\/tr>\n 194,409<\/b><\/p>\n<\/td>\n 194,847<\/b><\/p>\n<\/td>\n<\/tr>\n \n15,810<\/p>\n<\/td>\n \n16,081<\/p>\n<\/td>\n<\/tr>\n \n47,780<\/p>\n<\/td>\n \n51,043<\/p>\n<\/td>\n<\/tr>\n \n8,114<\/p>\n<\/td>\n \n8,424<\/p>\n<\/td>\n<\/tr>\n \n141,720<\/p>\n<\/td>\n \n140,867<\/p>\n<\/td>\n<\/tr>\n 213,423<\/b><\/p>\n<\/td>\n 216,414<\/b><\/p>\n<\/td>\n<\/tr>\n 407,833<\/b><\/p>\n<\/td>\n 411,262<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n 2023<\/b><\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n<\/tr>\n \n4,487<\/p>\n<\/td>\n \n4,487<\/p>\n<\/td>\n<\/tr>\n \n233,895<\/p>\n<\/td>\n \n233,895<\/p>\n<\/td>\n<\/tr>\n \n(5,097)<\/p>\n<\/td>\n \n(9,427)<\/p>\n<\/td>\n<\/tr>\n 233,285<\/b><\/p>\n<\/td>\n 228,955<\/b><\/p>\n<\/td>\n<\/tr>\n \n(34)<\/p>\n<\/td>\n \n(28)<\/p>\n<\/td>\n<\/tr>\n 233,251<\/b><\/p>\n<\/td>\n 228,928<\/b><\/p>\n<\/td>\n<\/tr>\n \n51,035<\/p>\n<\/td>\n \n55,873<\/p>\n<\/td>\n<\/tr>\n \n4,964<\/p>\n<\/td>\n \n5,147<\/p>\n<\/td>\n<\/tr>\n \n4,167<\/p>\n<\/td>\n \n4,312<\/p>\n<\/td>\n<\/tr>\n \n8,858<\/p>\n<\/td>\n \n9,277<\/p>\n<\/td>\n<\/tr>\n \n504<\/p>\n<\/td>\n \n1,611<\/p>\n<\/td>\n<\/tr>\n 69,528<\/b><\/p>\n<\/td>\n 76,220<\/b><\/p>\n<\/td>\n<\/tr>\n \n16,328<\/p>\n<\/td>\n \n17,058<\/p>\n<\/td>\n<\/tr>\n \n2,924<\/p>\n<\/td>\n \n2,902<\/p>\n<\/td>\n<\/tr>\n \n23,776<\/p>\n<\/td>\n \n23,230<\/p>\n<\/td>\n<\/tr>\n \n1,922<\/p>\n<\/td>\n \n1,246<\/p>\n<\/td>\n<\/tr>\n \n43,474<\/p>\n<\/td>\n \n41,721<\/p>\n<\/td>\n<\/tr>\n \n16,630<\/p>\n<\/td>\n \n19,957<\/p>\n<\/td>\n<\/tr>\n 105,054<\/b><\/p>\n<\/td>\n 106,114<\/b><\/p>\n<\/td>\n<\/tr>\n 407,833<\/b><\/p>\n<\/td>\n 411,262<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n Consolidated statement of cash flows (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n 2023<\/b><\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n<\/tr>\n \n3,715<\/p>\n<\/td>\n \n127<\/p>\n<\/td>\n<\/tr>\n \n3,637<\/p>\n<\/td>\n \n3,840<\/p>\n<\/td>\n<\/tr>\n \n1,674<\/p>\n<\/td>\n \n1,602<\/p>\n<\/td>\n<\/tr>\n \n–<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n<\/tr>\n \n–<\/p>\n<\/td>\n \n(48)<\/p>\n<\/td>\n<\/tr>\n \n(22)<\/p>\n<\/td>\n \n(18)<\/p>\n<\/td>\n<\/tr>\n \n(618)<\/p>\n<\/td>\n \n2<\/p>\n<\/td>\n<\/tr>\n \n109<\/p>\n<\/td>\n \n130<\/p>\n<\/td>\n<\/tr>\n \n(767)<\/p>\n<\/td>\n \n(1,618)<\/p>\n<\/td>\n<\/tr>\n \n1,375<\/p>\n<\/td>\n \n1,237<\/p>\n<\/td>\n<\/tr>\n \n6<\/p>\n<\/td>\n \n(28)<\/p>\n<\/td>\n<\/tr>\n \n717<\/p>\n<\/td>\n \n302<\/p>\n<\/td>\n<\/tr>\n 850<\/i><\/p>\n<\/td>\n 5,923<\/i><\/p>\n<\/td>\n<\/tr>\n \n3,363<\/p>\n<\/td>\n \n4,506<\/p>\n<\/td>\n<\/tr>\n \n262<\/p>\n<\/td>\n \n(1,357)<\/p>\n<\/td>\n<\/tr>\n \n1,368<\/p>\n<\/td>\n \n3,665<\/p>\n<\/td>\n<\/tr>\n \n(4,142)<\/p>\n<\/td>\n \n(891)<\/p>\n<\/td>\n<\/tr>\n \n367<\/p>\n<\/td>\n \n(341)<\/p>\n<\/td>\n<\/tr>\n 11,044<\/b><\/p>\n<\/td>\n 11,111<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n 2023<\/b><\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n<\/tr>\n \n(2,532)<\/p>\n<\/td>\n \n(2,376)<\/p>\n<\/td>\n<\/tr>\n \n(738)<\/p>\n<\/td>\n \n(1,123)<\/p>\n<\/td>\n<\/tr>\n \n100<\/p>\n<\/td>\n \n93<\/p>\n<\/td>\n<\/tr>\n \n–<\/p>\n<\/td>\n \n(27,414)<\/p>\n<\/td>\n<\/tr>\n (3,171)<\/b><\/p>\n<\/td>\n (30,820)<\/b><\/p>\n<\/td>\n<\/tr>\n \n(5,635)<\/p>\n<\/td>\n \n(5,969)<\/p>\n<\/td>\n<\/tr>\n \n(859)<\/p>\n<\/td>\n \n(881)<\/p>\n<\/td>\n<\/tr>\n \n(417)<\/p>\n<\/td>\n \n(515)<\/p>\n<\/td>\n<\/tr>\n \n(108)<\/p>\n<\/td>\n \n(89)<\/p>\n<\/td>\n<\/tr>\n (7,019)<\/b><\/p>\n<\/td>\n (7,452)<\/b><\/p>\n<\/td>\n<\/tr>\n 854<\/b><\/p>\n<\/td>\n (27,161)<\/b><\/p>\n<\/td>\n<\/tr>\n \n140,867<\/p>\n<\/td>\n \n196,028<\/p>\n<\/td>\n<\/tr>\n \n(1)<\/p>\n<\/td>\n \n743<\/p>\n<\/td>\n<\/tr>\n 141,720<\/b><\/p>\n<\/td>\n 169,610<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n 2023<\/b><\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n 3,715<\/b><\/p>\n<\/td>\n 127<\/b><\/p>\n<\/td>\n \n718<\/p>\n<\/td>\n \n298<\/p>\n<\/td>\n \n1,375<\/p>\n<\/td>\n \n1,289<\/p>\n<\/td>\n \n(809)<\/p>\n<\/td>\n \n(1,665)<\/p>\n<\/td>\n \n5,311<\/p>\n<\/td>\n \n5,442<\/p>\n<\/td>\n 10,310<\/b><\/p>\n<\/td>\n 5,491<\/b><\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n(48)<\/p>\n<\/td>\n 10,310<\/b><\/p>\n<\/td>\n 5,443<\/b><\/p>\n<\/td>\n Segment P&L (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n \n11,350<\/p>\n<\/td>\n \n24,317<\/p>\n<\/td>\n \n30,219<\/p>\n<\/td>\n \n65,886<\/p>\n<\/td>\n \n0<\/p>\n<\/td>\n \n65,886<\/p>\n<\/td>\n<\/tr>\n \n2,427<\/p>\n<\/td>\n \n7,348<\/p>\n<\/td>\n \n3,189<\/p>\n<\/td>\n \n12,964<\/p>\n<\/td>\n \n(2,655)<\/p>\n<\/td>\n \n10,310<\/p>\n<\/td>\n<\/tr>\n \n21.4%<\/p>\n<\/td>\n \n30.2%<\/p>\n<\/td>\n \n10.6%<\/p>\n<\/td>\n \n19.7%<\/p>\n<\/td>\n \n15.6%<\/p>\n<\/td>\n<\/tr>\n \n10,483<\/p>\n<\/td>\n \n18,347<\/p>\n<\/td>\n \n24,131<\/p>\n<\/td>\n \n52,961<\/p>\n<\/td>\n \n0<\/p>\n<\/td>\n \n52,961<\/p>\n<\/td>\n<\/tr>\n \n1,932<\/p>\n<\/td>\n \n3,227<\/p>\n<\/td>\n \n2,613<\/p>\n<\/td>\n \n7,772<\/p>\n<\/td>\n \n(2,329)<\/p>\n<\/td>\n \n5,443<\/p>\n<\/td>\n<\/tr>\n \n18.4%<\/p>\n<\/td>\n \n17.6%<\/p>\n<\/td>\n \n10.8%<\/p>\n<\/td>\n \n14.7%<\/p>\n<\/td>\n \n10.3%<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nUnallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n 2023 <\/b><\/p>\n<\/td>\n 2022 <\/b><\/p>\n<\/td>\n<\/tr>\n 3,715 <\/b><\/p>\n<\/td>\n 127 <\/b><\/p>\n<\/td>\n<\/tr>\n \n718<\/p>\n<\/td>\n \n298<\/p>\n<\/td>\n<\/tr>\n \n1,375<\/p>\n<\/td>\n \n1,289<\/p>\n<\/td>\n<\/tr>\n \n(809)<\/p>\n<\/td>\n \n(1,665)<\/p>\n<\/td>\n<\/tr>\n 4,998 <\/b><\/p>\n<\/td>\n 49 <\/b><\/p>\n<\/td>\n<\/tr>\n \n5,311<\/p>\n<\/td>\n \n5,442<\/p>\n<\/td>\n<\/tr>\n \n722<\/p>\n<\/td>\n \n816<\/p>\n<\/td>\n<\/tr>\n \n2,640<\/p>\n<\/td>\n \n2,106<\/p>\n<\/td>\n<\/tr>\n \n(707)<\/p>\n<\/td>\n \n(640)<\/p>\n<\/td>\n<\/tr>\n 12,964 <\/b><\/p>\n<\/td>\n 7,772 <\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\u00a0<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230427005072\/en\/<\/a><\/span><\/p>\n \nInvestor Relations KEYWORDS:<\/b> Belgium Europe<\/p>\n INDUSTRY KEYWORDS:<\/b> Electronic Design Automation Health Technology Health Technology Other Health Software General Health<\/p>\n\n
\n
\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n for the three months ended
March 31,<\/b><\/td>\n<\/tr>\n\n In ‘000<\/td>\n \n \n \n \n \n \n \n \n \n U.S.$<\/b><\/td>\n \n \u20ac<\/b><\/td>\n \n \u20ac<\/b><\/td>\n<\/tr>\n \n Revenue<\/td>\n \n \n \n \n \n \n \n Cost of Sales<\/td>\n \n \n \n \n \n \n \n Gross Profit<\/b><\/td>\n \n \n \n \n \n \n \n Gross profit as % of revenue<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Research and development expenses<\/td>\n \n \n \n \n \n \n \n Sales and marketing expenses<\/td>\n \n \n \n \n \n \n \n General and administrative expenses<\/td>\n \n \n \n \n \n \n \n Net other operating income (expenses)<\/td>\n \n \n \n \n \n \n \n Operating (loss) profit<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Financial expenses<\/td>\n \n \n \n \n \n \n \n Financial income<\/td>\n \n \n \n \n \n \n \n Share in loss of joint venture<\/td>\n \n \n \n \n \n \n \n (Loss) profit before taxes<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Income Taxes<\/td>\n \n \n \n \n \n \n \n Net (loss) profit for the period<\/b><\/td>\n \n \n \n \n \n \n \n Net (loss) profit attributable to:<\/td>\n \n \n \n \n \n <\/tr>\n \n The owners of the parent<\/td>\n \n \n \n \n \n \n \n Non-controlling interest<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Earning per share attributable to owners of the parent<\/b><\/td>\n \n \n \n \n \n <\/tr>\n \n Basic<\/td>\n \n \n \n \n \n \n \n Diluted<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Weighted average basic shares outstanding<\/td>\n \n \n \n \n \n \n \n Weighted average diluted shares outstanding<\/td>\n \n \n \n \n \n \n \n
\n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n for the three months ended
March 31,<\/b><\/td>\n<\/tr>\n \n In 000\u20ac<\/td>\n \n \n \n \n \n \n <\/tr>\n \n \n \n U.S.$<\/b><\/td>\n \n \u20ac<\/b><\/td>\n \n \u20ac<\/b><\/td>\n <\/tr>\n \n Net profit (loss) for the period<\/b><\/td>\n \n \n \n \n \n \n <\/tr>\n \n Other comprehensive income<\/b><\/td>\n \n \n \n \n \n \n <\/tr>\n \n Recycling<\/i><\/b><\/td>\n \n \n \n \n \n \n <\/tr>\n \n Exchange difference on translation of foreign operations<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Non-recycling<\/b><\/td>\n \n \n \n \n \n \n <\/tr>\n \n Fair value adjustments through OCI – Equity instruments<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Other comprehensive income (loss), net of taxes<\/b><\/td>\n \n \n \n \n \n \n <\/tr>\n \n Total comprehensive income (loss) for the year, net of taxes<\/b><\/td>\n \n \n \n \n \n \n <\/tr>\n \n Total comprehensive income (loss) attributable to:<\/td>\n \n \n \n \n \n \n <\/tr>\n \n The owners of the parent<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Non-controlling interests<\/td>\n \n \n \n \n \n \n <\/tr>\n<\/table>\n \n
\n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n As of
March 31,<\/b><\/td>\n\n As of
December 31,<\/b><\/td>\n<\/tr>\n\n In 000\u20ac<\/td>\n \n \n \n \n \n Assets<\/b><\/td>\n \n \n \n <\/tr>\n \n Non-current assets<\/b><\/td>\n \n \n \n <\/tr>\n \n Goodwill<\/td>\n \n \n \n \n \n Intangible assets<\/td>\n \n \n \n \n \n Property, plant & equipment<\/td>\n \n \n \n \n \n Right-of-Use assets<\/td>\n \n \n \n \n \n Investments in joint ventures<\/td>\n \n \n \n \n \n Deferred tax assets<\/td>\n \n \n \n \n \n Investments in convertible loans<\/td>\n \n \n \n \n \n Investments in non-listed equity instruments<\/td>\n \n \n \n \n \n Other non-current assets<\/td>\n \n \n \n \n \n Total non-current assets<\/b><\/td>\n \n \n \n \n \n Current assets<\/b><\/td>\n \n \n \n <\/tr>\n \n Inventories<\/td>\n \n \n \n \n \n Trade receivables<\/td>\n \n \n \n \n \n Other current assets<\/td>\n \n \n \n \n \n Cash and cash equivalents<\/td>\n \n \n \n \n \n Total current assets<\/b><\/td>\n \n \n \n \n \n Total assets<\/b><\/td>\n \n \n \n \n \n
\n \n \n As of
March 31,<\/b><\/td>\n\n As of
December 31,<\/b><\/td>\n<\/tr>\n\n In 000\u20ac<\/td>\n \n \n \n \n \n Equity and liabilities<\/b><\/td>\n \n \n \n <\/tr>\n \n Equity<\/b><\/td>\n \n \n \n <\/tr>\n \n Share capital<\/td>\n \n \n \n \n \n Share premium<\/td>\n \n \n \n \n \n Retained earnings and other reserves<\/td>\n \n \n \n \n \n Equity attributable to the owners of the parent<\/b><\/td>\n \n \n \n \n \n Non-controlling interest<\/td>\n \n \n \n \n \n Total equity<\/b><\/td>\n \n \n \n \n \n Non-current liabilities<\/b><\/td>\n \n \n \n <\/tr>\n \n Loans & borrowings<\/td>\n \n \n \n \n \n Lease liabilities<\/td>\n \n \n \n \n \n Deferred tax liabilities<\/td>\n \n \n \n \n \n Deferred income<\/td>\n \n \n \n \n \n Other non-current liabilities<\/td>\n \n \n \n \n \n Total non-current liabilities<\/b><\/td>\n \n \n \n \n \n Current liabilities<\/b><\/td>\n \n \n \n <\/tr>\n \n Loans & borrowings<\/td>\n \n \n \n \n \n Lease liabilities<\/td>\n \n \n \n \n \n Trade payables<\/td>\n \n \n \n \n \n Tax payables<\/td>\n \n \n \n \n \n Deferred income<\/td>\n \n \n \n \n \n Other current liabilities<\/td>\n \n \n \n \n \n Total current liabilities<\/b><\/td>\n \n \n \n \n \n Total equity and liabilities<\/b><\/td>\n \n \n \n \n \n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n for the three months ended
March 31,<\/b><\/td>\n<\/tr>\n\n In 000\u20ac<\/td>\n \n \n \n \n \n Operating activities<\/b><\/td>\n \n \n \n <\/tr>\n \n Net (loss) profit for the period<\/td>\n \n \n \n \n \n Non-cash and operational adjustments<\/i><\/td>\n \n \n \n <\/tr>\n \n Depreciation of property plant & equipment<\/td>\n \n \n \n \n \n Amortization of intangible assets<\/td>\n \n \n \n \n \n Impairment of goodwill and intangible assets<\/td>\n \n \n \n \n \n Share-based payment expense<\/td>\n \n \n \n \n \n Loss (gain) on disposal of intangible assets and property, plant & equipment<\/td>\n \n \n \n \n \n Movement in provisions<\/td>\n \n \n \n \n \n Movement reserve for bad debt and slow moving inventory<\/td>\n \n \n \n \n \n Financial income<\/td>\n \n \n \n \n \n Financial expense<\/td>\n \n \n \n \n \n Impact of foreign currencies<\/td>\n \n \n \n \n \n (Deferred) income taxes<\/td>\n \n \n \n \n \n Working capital adjustments<\/i><\/td>\n \n \n \n \n \n Decrease (increase) in trade receivables and other receivables<\/td>\n \n \n \n \n \n Decrease (increase) in inventories and contracts in progress<\/td>\n \n \n \n \n \n Increase (decrease) in deferred revenue<\/td>\n \n \n \n \n \n Increase (decrease) in trade payables and other payables<\/td>\n \n \n \n \n \n Income tax paid & Interest received<\/td>\n \n \n \n \n \n Net cash flow from operating activities<\/b><\/td>\n \n \n \n \n \n
\n \n \n for the three months ended
March 31,<\/b><\/td>\n<\/tr>\n\n In 000\u20ac<\/td>\n \n \n \n \n \n Investing activities<\/b><\/td>\n \n \n \n <\/tr>\n \n Purchase of property, plant & equipment<\/td>\n \n \n \n \n \n Purchase of intangible assets<\/td>\n \n \n \n \n \n Proceeds from the sale of property, plant & equipment & intangible assets (net)<\/td>\n \n \n \n \n \n Acquisition of subsidiary (net of cash)<\/td>\n \n \n \n \n \n Net cash flow used in investing activities<\/b><\/td>\n \n \n \n \n \n Financing activities<\/b><\/td>\n \n \n \n <\/tr>\n \n Repayment of loans & borrowings<\/td>\n \n \n \n \n \n Repayment of leases<\/td>\n \n \n \n \n \n Interest paid<\/td>\n \n \n \n \n \n Other financial income (expense)<\/td>\n \n \n \n \n \n Net cash flow from (used in) financing activities<\/b><\/td>\n \n \n \n \n \n Net increase\/(decrease) of cash & cash equivalents<\/b><\/td>\n \n \n \n \n \n Cash & Cash equivalents at the beginning of the year<\/td>\n \n \n \n \n \n Exchange rate differences on cash & cash equivalents<\/td>\n \n \n \n \n \n Cash & cash equivalents at end of the period<\/b><\/td>\n \n \n \n \n \n
\n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n for the three months ended
March 31,<\/b><\/td>\n<\/tr>\n \n In 000\u20ac<\/td>\n \n \n \n \n <\/tr>\n \n Net profit (loss) for the period<\/b><\/td>\n \n \n \n \n <\/tr>\n \n Income taxes<\/td>\n \n \n \n \n <\/tr>\n \n Financial expenses<\/td>\n \n \n \n \n <\/tr>\n \n Financial income<\/td>\n \n \n \n \n <\/tr>\n \n Depreciation and amortization<\/td>\n \n \n \n \n <\/tr>\n \n EBITDA<\/b><\/td>\n \n \n \n \n <\/tr>\n \n Share-based compensation expense (1)<\/td>\n \n \n \n \n <\/tr>\n \n Adjusted EBITDA<\/b><\/td>\n \n \n \n \n <\/tr>\n<\/table>\n \n
\n (1)<\/td>\n \n Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.<\/td>\n<\/tr>\n<\/table>\n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n In 000\u20ac<\/td>\n \n Materialise
Software<\/b><\/td>\n\n Materialise
Medical<\/b><\/td>\n\n Materialise
Manufacturing<\/b><\/td>\n\n Total
segments<\/b><\/td>\n\n Unallocated (1)<\/b><\/td>\n \n Consolidated<\/b><\/td>\n<\/tr>\n \n For the three months ended March 31, 2023<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Revenues<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n Segment (adj) EBITDA<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n Segment (adj) EBITDA %<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n For the three months ended March 31, 2022<\/b><\/td>\n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Revenues<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n Segment (adj) EBITDA<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n Segment (adj) EBITDA %<\/td>\n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n (1)<\/td>\n \n \n \n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n for the three months ended
March 31,<\/b><\/td>\n<\/tr>\n\n In 000\u20ac<\/td>\n \n \n \n \n \n Net profit (loss) for the period<\/b><\/td>\n \u00a0<\/td>\n \n \u00a0<\/b><\/td>\n \n \n Income taxes<\/td>\n \n \n \n \n \n Financial cost<\/td>\n \u00a0<\/td>\n \n \u00a0<\/td>\n \n \n Financial income<\/td>\n \n \n \n \n \n Operating (loss) profit<\/b><\/td>\n \u00a0<\/b><\/td>\n \n \u00a0<\/b><\/td>\n \n \n Depreciation and amortization<\/td>\n \n \n \n \n \n Corporate research and development<\/td>\n \u00a0<\/td>\n \n \u00a0<\/td>\n \n \n Corporate headquarter costs<\/td>\n \n \n \n \n \n Other operating income (expense)\u00a0<\/td>\n \u00a0<\/td>\n \n \u00a0<\/td>\n \n \n Segment adjusted EBITDA<\/b><\/td>\n \n \n \n \n <\/p>\n
\n
Harriet Fried
\n
LHA
\n
212.838.3777
\n
hfried@lhai.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230427005072\/en\/600300\/3\/MTLS_Logo_Press_Release.jpg\"){kind=logo}
<\/td>\n<\/tr>\n